ES2180758T3 - Vacunas de pertussis acelulares y metodos de preparacion de las mismas. - Google Patents

Vacunas de pertussis acelulares y metodos de preparacion de las mismas.

Info

Publication number
ES2180758T3
ES2180758T3 ES96911887T ES96911887T ES2180758T3 ES 2180758 T3 ES2180758 T3 ES 2180758T3 ES 96911887 T ES96911887 T ES 96911887T ES 96911887 T ES96911887 T ES 96911887T ES 2180758 T3 ES2180758 T3 ES 2180758T3
Authority
ES
Spain
Prior art keywords
pertussis
preparation
fimbrial
vaccines
accelular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96911887T
Other languages
English (en)
Inventor
Raafat E F Fahim
John R Vose
John Thipphawong
Luis Barreto
Gail E D Jackson
Larry U L Tan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Sanofi Pasteur SA
Original Assignee
Aventis Pasteur Ltd
Aventis Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/433,646 external-priority patent/US5877298A/en
Application filed by Aventis Pasteur Ltd, Aventis Pasteur SA filed Critical Aventis Pasteur Ltd
Application granted granted Critical
Publication of ES2180758T3 publication Critical patent/ES2180758T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE PREPARA UNA PREPARACION DE AGLUTINOGENO FIMBRIAL A PARTIR DE UNA CEPA DE BORDETELLA, EN PARTICULAR UNA CEPA DE B. PERTUSSIS, MEDIANTE UN PROCEDIMIENTO DE MULTIPLES ETAPAS DE IMPLICA LA EXTRACCION DE LOS AGLUTINOGENOS FIMBRIALES DE UNA PASTA CELULAR Y LA CONCENTRACION Y PURIFICACION DEL MATERIAL EXTRAIDO. LA PREPARACION DE AGLUTINOGENOS FIMBRIALES PUEDE UTILIZARSE PARA PREPARAR VACUNAS DE PERTUSSIS ACELULARES CON OTROS AGENTES DE PERTUSSIS, INCLUYENDO LA TOXINA O EL TOXOIDE DE PERTUSSIS, LA PROTEINA DE 69 KDA Y HEMAGLUTININA FILAMENTOSA Y OTROS ANTIGENOS DE BORDETELLA. TALES VACUNAS CONFIEREN PROTECCION A AL MENOS UN 70 % DE LA POBLACION HUMANA DE RIESGO.
ES96911887T 1995-05-04 1996-05-02 Vacunas de pertussis acelulares y metodos de preparacion de las mismas. Expired - Lifetime ES2180758T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/433,646 US5877298A (en) 1995-05-04 1995-05-04 Acellular pertussis vaccines and methods of preparing thereof
US50174395A 1995-07-12 1995-07-12

Publications (1)

Publication Number Publication Date
ES2180758T3 true ES2180758T3 (es) 2003-02-16

Family

ID=27029924

Family Applications (2)

Application Number Title Priority Date Filing Date
ES96911887T Expired - Lifetime ES2180758T3 (es) 1995-05-04 1996-05-02 Vacunas de pertussis acelulares y metodos de preparacion de las mismas.
ES96911886T Expired - Lifetime ES2182971T3 (es) 1995-05-04 1996-05-02 Vacunas de pertussis acelulares y metodos de preparacion de las mismas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES96911886T Expired - Lifetime ES2182971T3 (es) 1995-05-04 1996-05-02 Vacunas de pertussis acelulares y metodos de preparacion de las mismas.

Country Status (17)

Country Link
US (1) US6399076B2 (es)
EP (7) EP0826001B1 (es)
CN (2) CN1198099A (es)
AT (3) ATE221081T1 (es)
AU (2) AU710538B2 (es)
BR (2) BR9608114A (es)
CA (3) CA2433502A1 (es)
DE (3) DE69638326D1 (es)
DK (3) DK0826001T3 (es)
ES (2) ES2180758T3 (es)
FR (1) FR16C0015I2 (es)
LU (1) LU93036I2 (es)
MX (1) MX9708481A (es)
NL (1) NL300804I2 (es)
NZ (2) NZ306391A (es)
PT (3) PT1393744E (es)
WO (2) WO1996034883A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646776B1 (fr) * 1989-05-12 1994-06-03 Pasteur Institut Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella
US6051240A (en) * 1994-04-28 2000-04-18 Takeda Chemical Industries, Ltd. Method of separating protective components of Bordetella pertussis
US6696065B1 (en) * 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
GB9611501D0 (en) * 1996-06-03 1996-08-07 Smithkline Beecham Biolog Vaccine compositions
BRPI9710460B8 (pt) * 1996-07-02 2021-05-25 Aventis Pasteur composição imunogênica multi-valente e composição de vacina
EP1123711B9 (en) * 1998-10-21 2009-08-12 The Kitasato Institute Attenuated toxins as adjuvants
CN1906307B (zh) * 2003-11-20 2011-08-24 圣诺菲·帕斯图尔公司 纯化百日咳毒素的方法及其中有用的肽
CN101203605B (zh) * 2004-12-17 2016-01-27 由卫生福利和体育大臣代表的荷兰王国 革兰氏阴性菌的lps的脱酰基化
CA2618306C (en) 2005-08-08 2014-10-21 Oregon Health & Science University Inactivating pathogens with hydrogen peroxide for vaccine production
EP1867638A1 (de) * 2006-06-16 2007-12-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verfahren zur kovalenten Verknüpfung zweier Moleküle mittels Diels-Alder-Reaktion mit inversem Elektronenbedarf
US8945582B2 (en) 2006-09-07 2015-02-03 Glaxosmithkline Biologicals S.A. Vaccine
CN100537767C (zh) * 2007-04-29 2009-09-09 中国药品生物制品检定所 百日咳疫苗保护性抗原的重组表达及其应用
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
US20100330158A1 (en) * 2009-03-31 2010-12-30 Innopharma, Llc Protein-assisted drug delivery system for the targeted administration of active agents
EP2430040A1 (en) 2009-05-11 2012-03-21 Novartis AG Antigen purification process for pertactin antigen
CN103814048A (zh) * 2011-09-20 2014-05-21 生物辐射实验室股份有限公司 从生物分子制剂中去除杀病毒剂
WO2013049535A2 (en) 2011-09-30 2013-04-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Influenza vaccine
CN102584958A (zh) * 2012-02-08 2012-07-18 北京天坛生物制品股份有限公司 百日咳杆菌69kd外膜蛋白的纯化方法
CN102793915B (zh) * 2012-07-25 2013-10-23 天津康希诺生物技术有限公司 一种无细胞百日咳疫苗的生产方法
AP2015008702A0 (en) 2013-03-08 2015-09-30 Crucell Holland Bv Acellular pertussis vaccine
CN107921407B (zh) 2015-06-05 2022-07-05 格雷斯公司 生物处理吸附澄清剂及其制备和使用方法
CN105106947A (zh) * 2015-07-21 2015-12-02 华兰生物工程股份有限公司 过氧化氢脱毒的无细胞百日咳疫苗及其制备方法
US11602559B2 (en) 2016-10-03 2023-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV-1 Env fusion peptide immunogens and their use
WO2018081832A1 (en) 2016-10-31 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide fragments from filoviruses and their uses
EP3600405B1 (en) 2017-03-24 2025-08-20 The United States of America, as represented by the Secretary, Department of Health and Human Services Glycan-masked engineered outer domains of hiv-1 gp120 and their use
KR102426041B1 (ko) * 2017-08-01 2022-07-29 주식회사 녹십자 냉동 및 해동 과정을 포함하는 백일해균 유래 단백질 수득 방법
EP3697440A1 (en) 2017-10-16 2020-08-26 The United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant hiv-1 envelope proteins and their use
US12053519B2 (en) 2018-09-23 2024-08-06 The United States Of America, As Represented By The Secretary Department Of Health And Human Services HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use
EP3870703A1 (en) 2018-10-22 2021-09-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant gp120 protein with v1-loop deletion
CN110358802B (zh) * 2019-08-16 2021-06-18 长春百克生物科技股份公司 一种去除百日咳组分菌毛蛋白2/3内毒素的方法
US12210017B2 (en) 2020-01-08 2025-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptides representing epitopes from filoviruses
CN112094354B (zh) * 2020-11-05 2021-02-02 苏州世诺生物技术有限公司 副鸡禽杆菌基因工程亚单位疫苗、其制备方法及应用
AU2022323509A1 (en) 2021-08-03 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
US20250197455A1 (en) 2022-03-27 2025-06-19 TThe United States of America, as represented by the Secretary, Department of Health and Human Servi Base-covered hiv-1 envelope ectodomains and their use
CN117417419B (zh) * 2023-01-10 2024-04-19 康希诺生物股份公司 一种百日咳毒素脱毒方法及无细胞百白破联合疫苗
WO2024249626A1 (en) 2023-05-30 2024-12-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 envelope triple tandem trimers and their use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258029A (en) 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
GB8601279D0 (en) * 1986-01-20 1986-02-26 Public Health Lab Service Purification of pertussis antigens
US4705686A (en) 1986-05-09 1987-11-10 American Cyanamid Process for the preparation of acellular Bordetalla pertussis vaccine
KR0168039B1 (ko) * 1987-09-04 1999-01-15 로버트 디. 웨스트 재조합 dna에서 유도한 보르데텔라 외독소 소단위체의 유사체 및 그를 포함하는 백신
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
GB8807860D0 (en) 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
US4967176A (en) * 1988-07-15 1990-10-30 Raychem Corporation Assemblies of PTC circuit protection devices
US5101014A (en) 1989-02-10 1992-03-31 United States Of America Process for the purification of a 69,000 da outer membrane protein of Bordetella pertussis
IL93957A0 (en) * 1989-03-31 1990-12-23 Univ Washington Bordetella outer membrane proteins,their use in vaccines and their expression
US5276142A (en) 1989-12-11 1994-01-04 American Cyanamid Company Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis
GB9007657D0 (en) * 1990-04-04 1990-05-30 Connaught Lab Purification of a pertussis outer membrane protein(omp69)
EP0484621A3 (en) * 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
US6051240A (en) * 1994-04-28 2000-04-18 Takeda Chemical Industries, Ltd. Method of separating protective components of Bordetella pertussis
FR2728170A1 (fr) * 1994-12-15 1996-06-21 Pasteur Institut Vaccin de type acellulaire anti-bordetella
US5877298A (en) * 1995-05-04 1999-03-02 Connaught Lab Acellular pertussis vaccines and methods of preparing thereof

Also Published As

Publication number Publication date
HK1016191A1 (zh) 1999-10-29
FR16C0015I1 (es) 2016-06-10
DE69622555T2 (de) 2003-03-27
EP1393744A1 (en) 2004-03-03
LU93036I2 (fr) 2016-06-21
DE69638326D1 (de) 2011-03-10
DK0826001T3 (da) 2002-11-18
AU5494096A (en) 1996-11-21
DE69625191D1 (de) 2003-01-16
MX9708481A (es) 1998-02-28
BR9608114A (pt) 2000-10-31
DK1393744T3 (da) 2011-05-30
CA2220063C (en) 2003-08-26
AU715417B2 (en) 2000-02-03
PT1393744E (pt) 2011-05-03
NZ306391A (en) 1999-03-29
ATE496634T1 (de) 2011-02-15
ES2182971T3 (es) 2003-03-16
EP1233022B1 (en) 2015-12-09
CA2433502A1 (en) 1996-11-07
WO1996034623A1 (en) 1996-11-07
DE69622555D1 (de) 2002-08-29
EP0826001A1 (en) 1998-03-04
FR16C0015I2 (fr) 2017-06-09
EP1234580A1 (en) 2002-08-28
US20010009666A1 (en) 2001-07-26
CA2220063A1 (en) 1996-11-07
WO1996034883A1 (en) 1996-11-07
PT826001E (pt) 2002-12-31
EP0824358B1 (en) 2002-12-04
PT824358E (pt) 2003-02-28
CA2220048A1 (en) 1996-11-07
DE69625191T2 (de) 2003-07-10
CA2220048C (en) 2006-03-07
CN1198099A (zh) 1998-11-04
EP1234579A1 (en) 2002-08-28
CN100387618C (zh) 2008-05-14
ATE221081T1 (de) 2002-08-15
NZ306392A (en) 1999-04-29
AU710538B2 (en) 1999-09-23
US6399076B2 (en) 2002-06-04
DK0824358T3 (da) 2003-01-27
EP0826001B1 (en) 2002-07-24
EP0824358A1 (en) 1998-02-25
CN1193324A (zh) 1998-09-16
EP1393744B1 (en) 2011-01-26
NL300804I2 (es) 2016-11-01
EP1405643A1 (en) 2004-04-07
ATE228851T1 (de) 2002-12-15
AU5494196A (en) 1996-11-21
EP1233022A1 (en) 2002-08-21
BR9608115A (pt) 2004-07-13

Similar Documents

Publication Publication Date Title
ES2180758T3 (es) Vacunas de pertussis acelulares y metodos de preparacion de las mismas.
ATE127345T1 (de) Stressproteine und verwendungen dafür.
ES2063965T3 (es) Vacunas para haemophilus influenzae no tipificable.
NL300402I1 (en) Method and manufacture of an acellular vaccine comprising Bordetella pertussis antigens
DE69022106D1 (de) Pertussistoxin-Mutanten, dieselbe produzierende Bordetella-Stämme und ihre Verwendung als Vakzin gegen Pertussis.
LU90203I2 (fr) Anatoxine diphtérique anatoxine tétanique trois antigènes coquelucheux purifiés (toxine pertussique tp hémagglutinine filamenteuse (haf) et pertactine (protéine de membrane externe 69 kd) et le principal antigène de surface du virus de l'hépatite b (vhb) purfié (infanrix hepb) et ses dérivés pharmaceutiquement acceptables
ES2079851T3 (es) Uso de il-4 para mejorar la respuesta inmunitaria frente a inmunogenos en vacunas.
ATE385809T1 (de) Saponin-zusammensetzungen und deren verwendung
DE69123252D1 (de) Kreuzreaktive immunisierung gegen influenza
MX9708480A (es) Vacunas acelulares de pertussis y metodos de preparacion de las mismas.